Audentes Therapeutics Stock Forecast, Price & News

Audentes Therapeutics (NASDAQ:BOLD) Frequently Asked Questions

What stocks does MarketBeat like better than Audentes Therapeutics?

Wall Street analysts have given Audentes Therapeutics a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Audentes Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

How were Audentes Therapeutics' earnings last quarter?

Audentes Therapeutics Inc (NASDAQ:BOLD) released its earnings results on Thursday, November, 7th. The biotechnology company reported ($1.00) earnings per share for the quarter, topping analysts' consensus estimates of ($1.07) by $0.07. During the same period in the previous year, the business posted ($0.97) earnings per share.
View Audentes Therapeutics' earnings history.

Who are Audentes Therapeutics' key executives?

Audentes Therapeutics' management team includes the following people:

• Mr. Matthew R. Patterson, Co-Founder, Chairman & CEO (Age 47)
• Ms. Natalie C. Holles, Pres & COO (Age 46)
• Mr. Thomas P. Soloway, Exec. VP & CFO (Age 52)
• Dr. John T. Gray, Sr. VP & Chief Scientific Officer (Age 56)
• Mr. Andrew H. Chang, Director of Investor Relations

Who are some of Audentes Therapeutics' key competitors?

Some companies that are related to Audentes Therapeutics include Acceleron Pharma (XLRN), Neurocrine Biosciences (NBIX), CRISPR Therapeutics (CRSP), Exelixis (EXEL), Denali Therapeutics (DNLI), Beam Therapeutics (BEAM), Fate Therapeutics (FATE), Vir Biotechnology (VIR), Halozyme Therapeutics (HALO), Kodiak Sciences (KOD), Twist Bioscience (TWST), Adaptive Biotechnologies (ADPT), Adagio Therapeutics (ADGI), Abcam (ABCM) and Recursion Pharmaceuticals (RXRX).
View all of BOLD's competitors.

What other stocks do shareholders of Audentes Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Audentes Therapeutics investors own include Energy Transfer (ET), Gilead Sciences (GILD), CRISPR Therapeutics (CRSP), Intel (INTC), Clovis Oncology (CLVS), AbbVie (ABBV), bluebird bio (BLUE), Ford Motor (F), Global Blood Therapeutics (GBT) and Myriad Genetics (MYGN).

When did Audentes Therapeutics IPO?

(BOLD) raised $75 million in an initial public offering on Wednesday, July 20th 2016. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. BofA Merrill Lynch, Cowen and Company and Piper Jaffray served as the underwriters for the IPO and Wedbush PacGrow was co-manager.

What is Audentes Therapeutics' stock symbol?

Audentes Therapeutics trades on the NASDAQ under the ticker symbol "BOLD."

What is Audentes Therapeutics' stock price today?

One share of BOLD stock can currently be purchased for approximately $59.97.

How much money does Audentes Therapeutics make?

Audentes Therapeutics has a market capitalization of $2.77 billion. The biotechnology company earns $-128,820,000.00 in net income (profit) each year or ($3.40) on an earnings per share basis.

How many employees does Audentes Therapeutics have?

Audentes Therapeutics employs 207 workers across the globe.

What is Audentes Therapeutics' official website?

The official website for Audentes Therapeutics is www.audentestx.com.

Where are Audentes Therapeutics' headquarters?

Audentes Therapeutics is headquartered at 600 CALIFORNIA ST. 17TH FLOOR, SAN FRANCISCO CA, 94108.

How can I contact Audentes Therapeutics?

Audentes Therapeutics' mailing address is 600 CALIFORNIA ST. 17TH FLOOR, SAN FRANCISCO CA, 94108. The biotechnology company can be reached via phone at 415-818-1001 or via email at [email protected].